Enanta Pharmaceuticals’ (ENTA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $20.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.73) EPS, FY2027 earnings at ($2.53) EPS, FY2028 earnings at ($3.23) EPS, FY2029 earnings at ($2.40) EPS and FY2030 earnings at ($2.19) EPS.

Several other brokerages have also commented on ENTA. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, January 21st. JPMorgan Chase & Co. started coverage on shares of Enanta Pharmaceuticals in a research note on Friday, November 14th. They issued an “overweight” rating and a $17.00 price target for the company. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $20.33.

Enanta Pharmaceuticals Price Performance

Shares of ENTA opened at $13.84 on Tuesday. The company has a 50-day simple moving average of $14.10 and a two-hundred day simple moving average of $11.42. The firm has a market capitalization of $401.64 million, a PE ratio of -4.33 and a beta of 0.98. Enanta Pharmaceuticals has a one year low of $4.09 and a one year high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.12. The firm had revenue of $18.62 million during the quarter, compared to analyst estimates of $16.14 million. Enanta Pharmaceuticals had a negative return on equity of 78.58% and a negative net margin of 106.80%. Analysts expect that Enanta Pharmaceuticals will post -4.65 EPS for the current fiscal year.

Insider Activity at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly sold 4,743 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $14.23, for a total value of $67,492.89. Following the transaction, the chief executive officer owned 858,026 shares in the company, valued at approximately $12,209,709.98. This represents a 0.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Tara Lynn Kieffer sold 2,106 shares of the stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $14.23, for a total transaction of $29,968.38. Following the sale, the insider owned 30,620 shares in the company, valued at approximately $435,722.60. The trade was a 6.44% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 11,961 shares of company stock valued at $170,149. 11.48% of the stock is owned by insiders.

Institutional Trading of Enanta Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Deutsche Bank AG raised its stake in shares of Enanta Pharmaceuticals by 4.6% in the fourth quarter. Deutsche Bank AG now owns 24,107 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 1,055 shares during the last quarter. Public Employees Retirement System of Ohio increased its holdings in Enanta Pharmaceuticals by 8.3% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock worth $173,000 after buying an additional 1,100 shares in the last quarter. Ameriprise Financial Inc. raised its position in Enanta Pharmaceuticals by 8.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company’s stock worth $216,000 after buying an additional 1,383 shares during the last quarter. AlphaQuest LLC raised its position in Enanta Pharmaceuticals by 18.1% in the 3rd quarter. AlphaQuest LLC now owns 10,198 shares of the biotechnology company’s stock worth $122,000 after buying an additional 1,562 shares during the last quarter. Finally, Sio Capital Management LLC lifted its stake in Enanta Pharmaceuticals by 1.0% during the 2nd quarter. Sio Capital Management LLC now owns 178,774 shares of the biotechnology company’s stock valued at $1,352,000 after acquiring an additional 1,770 shares during the period. Institutional investors own 94.99% of the company’s stock.

Key Enanta Pharmaceuticals News

Here are the key news stories impacting Enanta Pharmaceuticals this week:

• Positive Sentiment: Zacks upgraded ENTA to a Zacks Rank #2 (Buy), a near‑term bullish signal that can attract momentum traders and retail investors. Zacks Upgrade
• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $20 price target and raised several medium‑ and long‑term EPS forecasts (FY2027–FY2030 and multiple quarters), which supports a constructive longer‑term thesis. HC Wainwright Note (MarketBeat)
• Positive Sentiment: An AAII writeup highlighted reasons the stock recently rallied (article framed why ENTA was up ~6%), which can amplify retail interest and explain recent intraday volatility. AAII: Why ENTA Is Up
• Neutral Sentiment: Short‑interest reports flagged a “large increase” in February but the published figures show 0 shares and NaN changes — indicating a likely data/reporting error. The ambiguous short‑interest read reduces clarity about bearish positioning and is unlikely by itself to explain a sustained move. (No external link available)
• Negative Sentiment: Within HC Wainwright’s update, the firm lowered its Q4 2026 EPS estimate (from ($0.56) to ($0.73)), a near‑term negative revision that could pressure sentiment despite the firm’s overall Buy stance and higher multi‑year estimates. HC Wainwright Note (MarketBeat)

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.